Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Panitumumab
panitumumab, mytomicin C, 5-FU, radiation · 1 trial · 1 indication
To estimate the three-year disease-free survival rate in patients treated with 5-FU, mytomicin C and Panitumumab concurrently with radiation therapy as treatment for anal squamous cell carcinoma
| Arm | Type | Description |
|---|---|---|
| Panitumumab, mytomicin C, 5-FU, radiation | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| panitumumab, mytomicin C, 5-FU, radiation | DRUG | Radiation therapy will be administered concurrent with chemotherapy and Panitumumab treatment. It will start the day 1 of the systemic treatment. That is, the first day of radiation therapy will be the day of the administration of the first dose of Panitumumab and Mitomycin C, as well as the first day of the first 96-hours course of 5-FU continuous infusion. On day 1, drugs and radiation will be administered in the following order: * First, Panitumumab. Panitumumab will be administered by IV infusion on day 1, and every 2 weeks during 8 weeks * Then Mitomycin C, 10mg/m2 on days 1 and 29 * Then start the 5-FU continuous infusion, 1000mg/m2 on days 1-4 and 29-32 * Finally, no less than 2 hours after the start of the 5-FU infusion, first dose of radiation therapy. |
Inclusion Criteria: * Man or woman ≥ 18 years * Competent to comprehend, sign, and date an IEC-approved informed consent form * Histologically or cytologically-confirmed anal canal SCC * T status 2-4 and any N status (pelvic or inguinal) radiologically defined by MRI * De novo diagnosis of anal can...
Panitumumab is an investigational drug being studied for use in colorectal cancer, tumors, cancer of the esophagus, mucinous adenocarcinoma of the colon, advanced renal cell carcinoma, and metastatic colorectal cancer. It is currently in Phase 2 clinical development for these oncology indications.
Panitumumab is a monoclonal antibody, indicated by its -mab suffix, that targets the epidermal growth factor receptor (EGFR). It is being studied in various solid tumors, including colorectal cancer and non-small-cell lung cancer, where EGFR signaling is often dysregulated.
Panitumumab is developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. Amgen is conducting clinical trials to evaluate the drug's safety and efficacy in multiple oncology indications.
Panitumumab is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The drug is being studied in several cancer types, including colorectal cancer and head and neck cancer, but remains in clinical trials.
Panitumumab has been studied in several clinical trials, including NCT00658658 in children with solid tumors, NCT00756444 in head and neck cancer, NCT01042288 in non-small-cell lung cancer, and NCT01285778 in anal cancer. These trials are completed, with a total enrollment of 4111 patients across all studies.
Yes, Panitumumab is also known as Vectibix. In clinical trial NCT01285778, the drug is referred to as Vectibix for the treatment of anal squamous cell carcinoma. This alternative name is used in some research contexts.